SAN DIEGO, Aug. 1, 2013 /PRNewswire/ --Organovo Holdings,
Inc. (NYSE MKT: ONVO) today announced that it intends to offer and
sell shares of its common stock in an underwritten public offering.
The offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering. Organovo also
expects to grant the underwriters a 30-day option to purchase up to
an additional 15% of the shares of common stock offered in the
public offering to cover over-allotments, if any. All of the shares
in the offering are to be sold by Organovo.
Lazard Capital Markets LLC and Oppenheimer & Co. Inc. are
acting as joint book-runners for the offering.
A shelf registration statement on Form S-3 relating to the
public offering of the shares of common stock described above was
filed with the Securities and Exchange Commission (SEC) and
declared effective by the SEC on July 26,
2013. A preliminary prospectus supplement relating to and
describing the terms of the offering will be filed with the SEC and
will be available on the SEC's web site at www.sec.gov. When
available, copies of the preliminary prospectus supplement relating
to these securities may also be obtained from the offices of Lazard
Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor,
New York, NY, 10020 or via
telephone at (800) 542-0970, or the offices of Oppenheimer &
Co. Inc., Attn: Syndicate Department, at 85 Broad Street, 26th
Floor, New York, NY, 10004 or via
email at equityprospectus@opco.com or via telephone at (212)
667-8563.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of these securities, nor will
there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale is not
permitted.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human
tissues for medical research and therapeutic applications. The
company is collaborating with pharmaceutical and academic partners
to develop human biological disease models in three dimensions.
These 3D human tissues have the potential to accelerate the drug
discovery process, enabling treatments to be developed faster and
at lower cost. In addition to numerous scientific publications,
their technology has been featured in The Wall Street Journal, Time
Magazine, The Economist, and numerous others. Organovo is changing
the shape of medical research and practice. Learn more at
www.organovo.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the
Company's ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; the availability of substantial additional
funding for the Company to continue its operations and to conduct
research and development, clinical studies and future product
commercialization; and the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies. These and other factors are identified and
described in more detail in the Company's filings with the SEC,
including the preliminary prospectus supplement filed with the SEC
on August 1, 2013 and the transition
report on Form 10-KT filed with the SEC on May 24, 2013 and its other filings with the
Securities and Exchange Commission. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the
United States, we do not intend to update any of the
forward-looking statements to conform these statements to reflect
actual results, later events or circumstances or to reflect the
occurrence of unanticipated events.
SOURCE Organovo Holdings, Inc.
